SCHEMBL4500756

SCHEMBL4500756

COc1ccc(CCC(O)CN2CCN(CC(=O)Nc3ccc4[nH]ncc4c3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.58
ROCK1 Q13464 3/20 0.58
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
CCR2 P41597 1/20 0.49
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 1/20 0.48
REV1 Q9UBZ9 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
PRKG1 Q13976 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490875 0.91 ROCK2 (0.55) ROCK2ROCK1NPC1RAB9AMEN1
SCHEMBL4866569 0.80 CYP3A4 (0.61) ROCK2ROCK1NPC1RAB9AMEN1
SCHEMBL12339946 0.77 MEN1 (0.73) ROCK2ROCK1NPC1RAB9AMEN1
SCHEMBL6285294 0.76 CYP2D6 (0.62) MEN1KMT2AALDH1A1KDM4E
SCHEMBL4500886 0.76 ROCK2 (0.62) ROCK2ROCK1NPC1RAB9AMEN1
SCHEMBL4866123 0.75 CYP3A4 (0.73)
SCHEMBL5413607 0.75 CHRNB2 (0.66) ROCK2ROCK1MEN1KMT2ACHRNB2
SCHEMBL4865890 0.75 CHRNB2 (0.56) ROCK2ROCK1NPC1MEN1KMT2A
SCHEMBL4867408 0.74 CYP3A4 (0.60)
SCHEMBL3829454 0.74 CHRNB2 (0.56) ROCK2ROCK1KMT2ACHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US claimed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US claimed
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US disclosed
US-7205303-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-04-17 US disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176356-A1 Substituted heterocyclic compounds KCNH1, KCNJ2, SCN5A ROCK2 4613/4885ROCK1 4675/4885NPC1 1980/4885
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A ROCK2 4761/4885ROCK1 4757/4885NPC1 2349/4885
US-20070155728-A1 Substituted Heterocyclic Compounds KCNH1, SDHA, COQ8A ROCK2 4761/4885ROCK1 4757/4885NPC1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.